MX343925B - Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. - Google Patents

Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.

Info

Publication number
MX343925B
MX343925B MX2012001061A MX2012001061A MX343925B MX 343925 B MX343925 B MX 343925B MX 2012001061 A MX2012001061 A MX 2012001061A MX 2012001061 A MX2012001061 A MX 2012001061A MX 343925 B MX343925 B MX 343925B
Authority
MX
Mexico
Prior art keywords
water
backbone moieties
polyethylene glycol
hydrogel
hydrogels
Prior art date
Application number
MX2012001061A
Other languages
English (en)
Other versions
MX2012001061A (es
Inventor
Hersel Ulrich
Rau Harald
Vetter Dirk
Krusch Mathias
Voigt Tobias
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of MX2012001061A publication Critical patent/MX2012001061A/es
Publication of MX343925B publication Critical patent/MX343925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

La presente invención se refiere a hidrogeles insolubles en agua a base de polietilenglicol biodegradables que comprende porciones de armazón principal que están interconectadas por enlaces hidrolíticamente degradables, las porciones de armazón principal comprenden además grupos funcionales reactivos, en donde el hidrogel insoluble en agua se caracteriza además porque la relación entre el periodo de tiempo para la degradación completa del hidrogel por hidrólisis de los enlaces degradables en productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal y el periodo de tiempo para liberación de los primeros 10% molares de productos de degradación hidrosolubles que comprenden una o más porciones de armazón principal con base en la cantidad total de porciones de armazón principal en el hidrogel es mayor que 1 e igual a o menor que 2. La invención se refiere además a conjugados de estos hidrogeles con ligandos o grupos de ligación, profármacos y composiciones farmacéuticas, así como a su uso en un medicamento.
MX2012001061A 2009-07-31 2010-07-30 Hidrogeles biodegradables insolubles en agua a base de polietilenglicol. MX343925B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167026 2009-07-31
EP09172339 2009-10-06
PCT/EP2010/061155 WO2011012715A1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels

Publications (2)

Publication Number Publication Date
MX2012001061A MX2012001061A (es) 2012-03-26
MX343925B true MX343925B (es) 2016-11-29

Family

ID=43027631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001061A MX343925B (es) 2009-07-31 2010-07-30 Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.

Country Status (23)

Country Link
US (1) US11559482B2 (es)
EP (2) EP2459220B1 (es)
JP (1) JP5904941B2 (es)
KR (1) KR101770844B1 (es)
CN (1) CN102573913B (es)
AU (1) AU2010277556B2 (es)
BR (1) BR112012002280B1 (es)
CA (1) CA2769162C (es)
ES (1) ES2833035T3 (es)
HK (1) HK1173082A1 (es)
HR (1) HRP20201609T1 (es)
HU (1) HUE052816T2 (es)
IL (1) IL217743A (es)
LT (1) LT2459220T (es)
MX (1) MX343925B (es)
MY (1) MY156872A (es)
NZ (1) NZ597960A (es)
PL (1) PL2459220T3 (es)
RU (1) RU2554854C9 (es)
SG (1) SG177761A1 (es)
SI (1) SI2459220T1 (es)
WO (1) WO2011012715A1 (es)
ZA (1) ZA201200686B (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598021A (en) * 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
MX2012001141A (es) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Composicion de insulina de accion prolongada.
CN102686245B (zh) 2009-10-29 2015-09-30 阿森迪斯药物股份有限公司 可生物降解水凝胶的消毒
SI2512450T1 (en) 2009-12-15 2018-05-31 Ascendis Pharma Endocrinology Division A/S A dry growth hormone composition transiently bound to a polymeric carrier
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
WO2012151051A1 (en) * 2011-05-03 2012-11-08 Telik, Inc. Excipient compatibility with ezatiostat
CN103889434B (zh) * 2011-06-21 2017-02-15 Bvw控股公司 含有乳香酸的医疗装置
BR112014003225A2 (pt) * 2011-08-12 2017-03-01 Ascendis Pharma As profármacos de treprostinil ligados a veículo
AU2012296955B2 (en) 2011-08-12 2016-12-15 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
CA2843881C (en) * 2011-08-12 2020-05-26 Ascendis Pharma A/S Sustained release composition of prostacyclin
WO2013053856A1 (en) * 2011-10-12 2013-04-18 Ascendis Pharma A/S Prevention and treatment of ocular conditions
AU2012331279A1 (en) * 2011-11-03 2014-05-08 Bayer Intellectual Property Gmbh Tyrosine based linkers for the releasable connection of peptides
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
WO2013160340A1 (en) 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
WO2014031630A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone and use thereof
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
CN110003201A (zh) * 2012-08-21 2019-07-12 詹森药业有限公司 帕潘立酮半抗原
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
CA2882449C (en) 2012-08-21 2018-09-04 Ronghui Lin Haptens of aripiprazole and their use in immunoassays
WO2014031635A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to aripiprazole haptens and use thereof
EP2888287A4 (en) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
MY177912A (en) 2012-10-11 2020-09-25 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
MX2015003792A (es) * 2012-10-11 2015-07-14 Ascendis Pharma As Profarmacos de hidrogel.
JP6355636B2 (ja) * 2012-10-11 2018-07-11 アセンディス ファーマ エー／エス 関節の疾患の診断、予防及び治療
WO2014086961A1 (en) 2012-12-07 2014-06-12 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
US20140271885A1 (en) * 2013-03-15 2014-09-18 Intezyne Technologies, Inc. Copolymers for stable micelle formulations
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
DK2988732T3 (da) * 2013-04-22 2023-06-26 Ascendis Pharma As Modificerede hydrogeler
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
RU2543375C1 (ru) * 2013-07-29 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение производного метилурацила с органической кислотой и способ его получения
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
US20180042996A1 (en) * 2013-10-08 2018-02-15 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-Linked IL-1ra Prodrug
CN103554296B (zh) * 2013-10-12 2015-09-16 天津大学 一种亚油酸改性葡聚糖及制备高分子脂质体的方法
EP3068438A1 (en) 2013-11-11 2016-09-21 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
US9675607B2 (en) * 2013-11-13 2017-06-13 Northwestern University Epimorphic regeneration and related hydrogel delivery systems
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103706233A (zh) * 2013-12-17 2014-04-09 杨亮月 一种环氧乙烷零排放处理体系及方法
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
BR112017000813B1 (pt) 2014-07-17 2021-03-16 The Regents Of The University Of California sistemas de gel microporoso, usos de uma pluralidade de partículas de microgel em uma solução aquosa e um agente de recozimento, de camadas de sequestrantes covalentemente estabilizados de partículas de microgel, e de um sequestrante covalentemente estabilizado de partículas de microgel com espaços intersticiais, bem como método para a preparação de partículas de microgel
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9923177B2 (en) * 2014-08-21 2018-03-20 Johnson & Johnson Vision Care, Inc. Biocompatibility of biomedical energization elements
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6723509B2 (ja) 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
EP3353203A2 (en) 2015-09-23 2018-08-01 H. Hoffnabb-La Roche Ag Optimized variants of anti-vegf antibodies
WO2017062770A1 (en) * 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
US10155063B2 (en) 2015-11-12 2018-12-18 University Of Virginia Patent Foundation Methods for vas-occlusive contraception and reversal thereof
MA44056A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps anti-rispéridone et leur utilisation
CN108697640A (zh) * 2015-12-18 2018-10-23 韩捷 一种可在生理条件下降解的水凝胶
WO2017112704A1 (en) 2015-12-23 2017-06-29 Viking Scientific, Inc. Hydrogel prodrug for treatment
WO2017142879A1 (en) 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
MY196308A (en) 2016-03-01 2023-03-24 Ascendis Pharma Bone Diseases As PTH Prodrugs
US10842743B2 (en) 2016-04-08 2020-11-24 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
CN105963792B (zh) * 2016-04-29 2019-03-22 深圳迈普再生医学科技有限公司 医用水凝胶组合物，医用水凝胶及其制备方法与应用
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
CN117257922A (zh) 2016-09-29 2023-12-22 阿森迪斯药物骨疾病股份有限公司 具有低峰-谷比的pth化合物
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
CA3037444A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
CN110446508A (zh) 2016-12-29 2019-11-12 泰普治疗公司 用于治疗医疗植入物部位的方法和系统
FI3592392T3 (fi) 2017-03-10 2023-11-09 Univ Louisville Res Found Inc Fasl-muunneltuja biomateriaaleja, joilla on immunomodulatorista toimintaa
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108864258A (zh) * 2017-05-12 2018-11-23 北京康明海慧生物科技有限公司 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107583104B (zh) * 2017-10-31 2020-12-01 无锡中科光远生物材料有限公司 一种可注射的用于脊柱修复的凝胶材料
US20200345857A1 (en) * 2017-11-02 2020-11-05 Tarsius Pharma Ltd. Phosphorylcholine-tuftsin conjugate for treating ocular inflammation
CN107880288A (zh) * 2017-11-29 2018-04-06 桂林华诺威生物科技有限公司 一种透明质酸钠凝胶的制备方法
CN108096630B (zh) * 2018-01-29 2020-09-04 暨南大学 一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
CN110865130B (zh) * 2018-08-27 2023-08-22 北京海晶生物医药科技有限公司 一种盐酸奥洛他定及其有关物质的检测方法
MX2021003186A (es) 2018-09-26 2021-07-16 Ascendis Pharma As Nuevos conjugados de hidrogel.
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN111077235B (zh) * 2018-10-19 2023-09-08 重庆医药工业研究院有限责任公司 一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
BR112021011592A2 (pt) * 2019-01-04 2021-10-26 Ascendis Pharma Oncology Division A/S Conjugados de agonistas de receptor de reconhecimento de padrão
SG11202105833WA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Minimization of systemic inflammation
US20220054477A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
SG11202104966XA (en) * 2019-01-04 2021-06-29 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
AU2020288650A1 (en) * 2019-06-07 2021-12-09 Likarda, LLC Tunable degradation in hydrogel microparticles
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
EP3986472A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254602A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
AU2020295721A1 (en) 2019-06-21 2021-12-23 Ascendis Pharma A/S Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
AU2020295725A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Anti-CTLA4 conjugates
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
CA3144333A1 (en) * 2019-06-26 2020-12-30 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
CN114466869B (zh) * 2019-07-03 2024-03-19 莫莉·桑德拉·萧伊凯特 水凝胶组合物及其用途
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
AU2020340441A1 (en) * 2019-08-29 2022-03-24 Paul Douglas Godfrin Hydrogels as oral delivery dosage forms, methods of making and using same
CN114846096A (zh) * 2019-11-19 2022-08-02 路博润先进材料公司 与双缩二胍成盐的聚氨酯组合物
US20230110994A1 (en) 2020-01-03 2023-04-13 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
CN111138293B (zh) * 2020-01-10 2023-07-07 蚌埠丰原医药科技发展有限公司 一种用微通道反应器合成富马酸伊布利特中间体的方法
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
KR102375663B1 (ko) * 2020-03-24 2022-03-16 재단법인대구경북과학기술원 무손실 세포 염색 방법 및 장치
BR112022018815A2 (pt) 2020-03-25 2022-11-29 Ocular Therapeutix Inc Implante ocular contendo um inibidor de tirosina cinase
EP4146281A1 (en) 2020-05-04 2023-03-15 Ascendis Pharma A/S Hydrogel irradiation
CN113694261B (zh) * 2020-05-21 2022-09-09 江苏百赛飞生物科技有限公司 一种抗菌复合涂层及其制备方法和制品
WO2021243309A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
AU2021286177A1 (en) 2020-06-03 2022-12-01 Ascendis Pharma Oncology Division A/S IL-2 sequences and uses thereof
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
BR112023003476A2 (pt) 2020-08-28 2023-04-11 Ascendis Pharma Oncology Div A/S Proteínas il-2 glicosiladas e usos das mesmas
JP2023543265A (ja) 2020-09-28 2023-10-13 アセンディス ファーマ ボーン ディジージズ エー／エス 副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
KR102437315B1 (ko) * 2020-11-02 2022-08-30 아주대학교산학협력단 하이브리드 하이드로겔 및 이의 생의학적 용도
BR112023018802A2 (pt) 2021-04-01 2023-10-31 Ascendis Pharma As Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
CN113304139B (zh) * 2021-06-30 2022-04-29 贵州医科大学 Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
CN113461979A (zh) * 2021-07-19 2021-10-01 吉林大学 一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
IL313041A (en) 2021-12-13 2024-07-01 Ascendis Pharma Oncology Div A/S Cancer treatments with TLR7/8 agonists
CN114469926B (zh) * 2022-01-28 2023-06-27 吉林省健维天然生物科技有限公司 二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
CN115109275B (zh) * 2022-08-29 2022-11-01 杭州艾名医学科技有限公司 一种动态交联可降解水凝胶、制备方法及应用
CN115444840B (zh) * 2022-09-15 2023-08-25 四川大学 一种前药、两性离子水凝胶及其制备方法、应用
CN115322397B (zh) * 2022-09-23 2024-04-30 福州大学 一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
CN115537017B (zh) * 2022-09-27 2023-09-01 四川大学 一种水凝胶及其制备方法和应用
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100266912B1 (ko) 1992-02-28 2000-12-01 파라비 레이 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1494757A2 (en) 2002-04-04 2005-01-12 Enzon, Inc. Polymeric acyl derivatives of indoles
ATE531447T1 (de) * 2003-01-17 2011-11-15 Cornell Res Foundation Inc Injizierbare hydrogel-microsphären aus wässrigem zwei-phasen-system
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
KR100665672B1 (ko) * 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2636957A1 (en) * 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
GB0619175D0 (en) * 2006-09-29 2006-11-08 Univ Nottingham Polymer
EP2099845B1 (en) 2006-11-27 2020-12-23 Actamax Surgical Materials LLC Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
WO2008097581A1 (en) * 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) * 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
BRPI0810530B8 (pt) 2007-04-13 2021-06-22 Kuros Biosurgery Ag composição, uso da mesma, biomaterial sintético, seu método de fabricação e kit para formar o mesmo
JP5588354B2 (ja) 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
EP3000462A1 (en) * 2008-04-28 2016-03-30 Zogenix, Inc. Novel formulations for treatment of migraine
CN102686245B (zh) * 2009-10-29 2015-09-30 阿森迪斯药物股份有限公司 可生物降解水凝胶的消毒
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
JP5904941B2 (ja) 2016-04-20
PL2459220T3 (pl) 2021-03-08
ES2833035T3 (es) 2021-06-14
RU2012107137A (ru) 2013-09-10
JP2013500950A (ja) 2013-01-10
IL217743A0 (en) 2012-03-29
SG177761A1 (en) 2012-03-29
RU2554854C2 (ru) 2015-06-27
KR20120090039A (ko) 2012-08-16
IL217743A (en) 2017-01-31
RU2554854C9 (ru) 2017-02-03
EP2459220A1 (en) 2012-06-06
US20120156259A1 (en) 2012-06-21
EP2459220B1 (en) 2020-09-09
MX2012001061A (es) 2012-03-26
SI2459220T1 (sl) 2020-12-31
CN102573913A (zh) 2012-07-11
LT2459220T (lt) 2020-12-28
ZA201200686B (en) 2012-10-31
AU2010277556A1 (en) 2012-02-02
WO2011012715A1 (en) 2011-02-03
AU2010277556B2 (en) 2014-10-09
EP3782649A1 (en) 2021-02-24
KR101770844B1 (ko) 2017-08-23
MY156872A (en) 2016-04-15
BR112012002280B1 (pt) 2020-04-07
CA2769162C (en) 2017-12-05
US11559482B2 (en) 2023-01-24
CN102573913B (zh) 2014-06-18
HUE052816T2 (hu) 2021-05-28
HRP20201609T1 (hr) 2021-01-08
CA2769162A1 (en) 2011-02-03
NZ597960A (en) 2013-07-26
BR112012002280A2 (pt) 2016-06-14
HK1173082A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
MX2012001061A (es) Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.
WO2011062965A3 (en) Targeting monomers and polymers having targeting blocks
WO2011163483A3 (en) Polymers for biomaterials and therapeutics
NZ592139A (en) Biodegradable polymer - bioactive moiety conjugates
WO2011112482A3 (en) Polymeric drug delivery conjugates and methods of making and using thereof
WO2011059326A3 (en) Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
MX341475B (es) Composiciones de copolimero hibrido para aplicaciones de cuidado personal.
MX2009008790A (es) Composiciones de suministro de agentes beneficos.
MX2009014279A (es) Cadenas laterales de ester de fenilo para incrementar la resortividad polimerica.
UA106570C2 (uk) Суміші полімолочної кислоти й розчинного у воді полімеру
WO2012008722A3 (ko) 조직 증강용 충전 조성물
EP2395048A3 (en) Polymers compositions including an antioxidant
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
IN2012DN00570A (es)
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
WO2009048930A3 (en) Crossed-linked hyaluronic acid and collagen and uses thereof
MY156373A (en) Biodegradable polymer composition
WO2012075086A3 (en) Fabric care composition
WO2007131193A3 (en) Main chain acid-degradable polymers for the delivery of bioactive materials
WO2008048775A3 (en) Gelled dairy compositions and related methods
WO2012017288A3 (en) Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
MX2012002643A (es) Diesteres aromaticos con grupos funcionales fluoroeter y derivados de estos.
GB2451599A (en) Nanostructures suitable for delivery of agents
MX2011007288A (es) Trozos en composicones alimenticias gelatinosas.
NZ606723A (en) Glatiramer acetate molecular weight markers

Legal Events

Date Code Title Description
FG Grant or registration